汕头白癜风医学研究院好不(白癜风纳入医保吗揭阳) (今日更新中)

BEIJING, Oct. 11 (Xinhuanet) -- Debates in the medical field developed on Monday as a U.S. government panel recommended that men of all ages should stop getting prostate cancer blood screenings.The United States Preventive Services examined all the evidence and found little if any reduction in deaths from routine P.S.A. screening and suggested that the test does more harm than good to healthy men.The P.S.A. test for prostate cancer, a blood test to screen for a protein that may indicate cancer, has become widely used because it can help detect tiny tumors at a very early sta ge, when they are theoretically most treatable.Unfortunately, according to the task force, the vast majority of the results are false-positives: the men don’t actually have cancer. And most of those found to have cancerous cells would not suffer ill effects because their cancer is so slow-growing that it would not cut short their lives. Those with faster-growing cancers may also not be helped if the cancer is extremely aggressive.After the recommendation came out last week, many prostate cancer specialists have been pushing back.Urologist Dr. Mark DeGuenther said this recommendation is more about saving money than saving lives. He said death rates from prostate cancer have dropped 40 percent since men began getting screened at age 40 and he says it will save taxpayers and patients more money in the long run to diagnose and treat cancers earlier rather than wait and have to provide expensive care for advanced stage cancers."We all agree that we've got to do a better job of figuring out who would benefit from P.S.A. screening," said Dr. Scott Eggener, a prostate cancer specialist at the University of Chicago. "But a blanket statement of just doing away with it altogether ... seems over-aggressive and irresponsible."Dr. Deepak Kapoor, chairman and chief executive of Integrated Medical Professionals, which includes the nation's largest urology practice, said "We will not allow patients to die, which is what will happen if this recommendation is accepted."That task force's recommendation isn't final - it's a draft open for public debate. And obviously the debate is already under way.

BEIJING, Jan. 25 (Xinhua) -- China's meteorological authority said Wednesday that most parts of China will continue to be in the grip of cold with temperatures remaining low over the next few days.Snowy weather is forecast to continue in the country's southern regions, and freezing rain is expected to hit parts of Guizhou and Hunan provinces, the National Meteorological Center said in a statement on its website.Parts of the country's northwest areas expected to see light snow or drizzle.Meanwhile, fog will shroud most parts of the country's southern areas Wednesday morning, reducing visibility in parts of Yunnan, Hunan, Jiangxi, and Zhejiang provinces to less than 1,000 meters, while smog is forecast to hit some areas of Jiangsu Province, according to the statement.

SYDNEY, Nov. 10 (Xinhua) -- Children with fat fathers are more likely to be obese by age of eight or nine than those with healthy weight fathers, a new study by researchers at Australia's University of Newcastle found on Thursday.Researchers at the University of Newcastle found that children who had an overweight or obese dad were four times more likely to follow in their father's footsteps than those with a dad in the healthy weight range.They also found in the study that only having an obese or overweight mum in the family did not have the same effect.Lead researcher Emily Freeman said it was still unknown why overweight dads had such a significant effect on their children's weights.The researchers conducted their study using data collected from 3000 Australian families between 2004 and 2008 for a longitudinal study.They looked at the weights of children when they were aged four to five and then again when they turned eight and nine years old.According to Freeman, around 25 percent of Australian children are overweight or obese.She said helping fat dads lose weight could make a difference to the youngsters.

RIYADH, Jan. 14 (Xinhua) -- China and Saudi Arabia pledged to work together to further expand all-around exchanges and cooperation as Chinese Premier Wen Jiabao Saturday unfolded his official visit to the Middle East kingdom.China and Saudi Arabia have treated each other as equals with respect and their cooperation has been fruitful since the establishment of diplomatic ties 22 years ago, said Wen while meeting Crown Prince Nayef bin Abdulaziz Al Saud.In recent years, despite the fact that international and regional situation became ever complicated and volatile, the two countries have strengthened high-level exchanges and promoted political mutual trust, said Wen, adding that the two have always demonstrated mutual understanding and support on issues involving their core interests and of major concern.Chinese Premier Wen Jiabao (L) holds talks with Saudi Arabia's Crown Prince Nayef bin Abdulaziz Al Saud in Riyadh, Saudi Arabia, Jan. 14, 2012.The premier said the decision to lift bilateral ties to an even higher level has shown the two nations' firm commitment to jointly face challenges and protect common interests as the world situation is undergoing profound changes.China would like to work with the Saudi side in deepening exchanges and cooperation in various aspects so as to benefit the two peoples and promote world peace and development, Wen added.He said the two sides should expand trade of crude oil and natural gas and energy-related cooperation as to deepen their energy partnership.Wen also asked the two countries to promote investment cooperation. The Chinese government encourages well-established Chinese companies to participate in Saudi Arabia's infrastructure construction such as railway, sea ports, electricity and telecommunications, he said.The two nations could also enhance security and law enforcement cooperation and promote people-to-people exchanges in areas like education and sports, as well as between the two nations' youths.Nayef said Saudi Arabia and China enjoy a time-honored history of exchanges, adding that the Saudi people have friendly feelings toward the Chinese people and expect even better bilateral ties.With joint efforts, bilateral ties have moved forward continuously with remarkable achievements in bilateral cooperation, he said, added that the partnership has bright prospects.Nayef said Saudi Arabia is willing to further boost political mutual trust with China, expand bilateral cooperation in economy and trade, energy, infrastructure, culture, press, and security, promote friendship between the two peoples, and lift bilateral ties to a higher level.Wen arrived here on Saturday evening after a short official visit to Nepal on the same day.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

来源：资阳报